ImmunoPrecise Antibodies Stock (NASDAQ:IPA)


OwnershipChartTranscripts

Previous Close

$2.16

52W Range

$0.27 - $2.41

50D Avg

$1.10

200D Avg

$0.61

Market Cap

$92.45M

Avg Vol (3M)

$2.41M

Beta

0.46

Div Yield

-

IPA Company Profile


ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

72

IPO Date

Jan 07, 2002

Website

IPA Performance


Latest Earnings Call Transcripts


Q3 25Mar 28, 25 | 10:30 AM
Q2 25Dec 10, 24 | 10:30 AM
Q1 25Sep 16, 24 | 10:30 AM

Peer Comparison


TickerCompany
TCRXTScan Therapeutics, Inc.
NRXPNRx Pharmaceuticals, Inc.
LEXXLexaria Bioscience Corp.
INABIN8bio, Inc.
ABSIAbsci Corporation
VRPXVirpax Pharmaceuticals, Inc.
MDIAMediaCo Holding Inc.
PRFXPainReform Ltd.
IMNMImmunome, Inc.